Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 32 Records) |
| Query Trace: Lung Neoplasms and MUT[original query] |
|---|
| Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients. Lung cancer (Amsterdam, Netherlands) 2014 Nov 86 (2): 164-9. Chao Liu, Yi-Sheng Huang, Yu Chen, Li-Xu Yan, Xin-Lan Luo, Dong-Lan Luo, Jie Chen, Yi-Lon Wu, Hui Liu Y |
| The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2014 Sep 9 (9): 1363-9. Izar Benjamin, Zhou Haiyu, Heist Rebecca S, Azzoli Christopher G, Muzikansky Alona, Scribner Emily E F, Bernardo Lindsay A, Dias-Santagata Dora, Iafrate Anthony J, Lanuti Micha |
| Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials. Medical science monitor : international medical journal of experimental and clinical research 2014 20 2666-76. Zhang Wen-Qian, Li Tong, Li H |
| Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 Dec . Zer Alona, Ding Keyue, Lee Siow Ming, Goss Glenwood D, Seymour Lesley, Ellis Peter M, Hackshaw Allan, Bradbury Penelope A, Han Lei, O'Callaghan Christopher J, Tsao Ming-Sound, Shepherd Frances |
| Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) 2017 Sep 111 23-29. Labbé Catherine, Cabanero Michael, Korpanty Grzegorz J, Tomasini Pascale, Doherty Mark K, Mascaux Céline, Jao Kevin, Pitcher Bethany, Wang Rick, Pintilie Melania, Leighl Natasha B, Feld Ronald, Liu Geoffrey, Bradbury Penelope Ann, Kamel-Reid Suzanne, Tsao Ming-Sound, Shepherd Frances |
| Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Molecular cancer 2018 Apr 17 (1): 81. Liu Liang, Ruiz Jimmy, O'Neill Stacey S, Grant Stefan C, Petty W Jeffrey, Yang Meng, Chen Kexin, Topaloglu Umit, Pasche Boris, Zhang W |
| Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer management and research 2019 11 5665-5675. Hou Helei, Qin Kang, Liang Yu, Zhang Chuantao, Liu Dong, Jiang Haiping, Liu Kewei, Zhu Jingjuan, Lv Hongying, Li Tianjun, Zhang Xiaoch |
| Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition. Cancer science 2019 Apr . Liang Wenhua, Guo Minzhang, Pan Zhenkui, Cai Xiuyu, Li Caichen, Zhao Yi, Liang Hengrui, Yang Haiying, Wang Zhen, Chen Wenting, Xu Chuhong, Yang Xinyun, Sun Jianyu, He Ping, Gu Xia, Yin Weiqiang, He Jianxi |
| High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. In vivo (Athens, Greece) 0 34 (4): 2009-2014. Santarpia Mariacarmela, Altavilla Giuseppe, Borsellino Nicolo, Girlando Andrea, Mancuso Gianfranco, Pergolizzi Stefano, Piazza Dario, Pontoriero Antonio, Valerio Maria Rosaria, Gebbia Vittor |
| Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. Journal of the National Comprehensive Cancer Network : JNCCN 2020 5 18 (5): 517-521. Chumsri Saranya, Sokol Ethan S, Soyano-Muller Aixa E, Parrondo Ricardo D, Reynolds Gina A, Nassar Aziza, Thompson E Aubr |
| The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients. Frontiers in oncology 2020 10 726. Liu Shaokun, Huang Tanxiao, Liu Ming, He Wenlong, Zhao YingShen, Yang Lizhen, Long Yingjiao, Zong Dandan, Zeng Huihui, Liu Yuanyuan, Liao Wenting, Duan Jingxian, Gong Subo, Chen Shi |
| Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Feb . Aggarwal Charu, Thompson Jeffrey C, Chien Austin L, Quinn Katie J, Hwang Wei-Ting, Black Taylor A, Yee Stephanie S, Christensen Theresa E, LaRiviere Michael J, Silva Benjamin A, Banks Kimberly C, Nagy Rebecca J, Helman Elena, Berman Abigail T, Ciunci Christine A, Singh Aditi P, Wasser Jeffrey S, Bauml Joshua M, Langer Corey J, Cohen Roger B, Carpenter Erica |
| Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). Cancer science 2020 Nov . Sakai Kazuko, Tsuboi Masahiro, Kenmotsu Hirotsugu, Yamanaka Takeharu, Takahashi Toshiaki, Goto Koichi, Daga Haruko, Ohira Tatsuo, Ueno Tsuyoshi, Aoki Tadashi, Nakagawa Kazuhiko, Yamazaki Koji, Hosomi Yukio, Kawaguchi Koji, Okumura Norihito, Takiguchi Yuichi, Sekine Akimasa, Haruki Tomohiro, Yamamoto Hiromasa, Sato Yuki, Akamatsu Hiroaki, Seto Takashi, Saeki Sho, Sugio Kenji, Nishio Makoto, Okabe Kazunori, Yamamoto Nobuyuki, Nishio Kazu |
| High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy. Cancer medicine 2021 Sep . Lyu Qiong, Zhu Weiliang, Wei Ting, Ding Weimin, Cao Manming, Wang Qiongyao, Guo Linlang, Luo Peng, Zhang Ji |
| Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Scientific reports 2021 Sep 11 (1): 18762. Morita Chie, Yoshida Tatsuya, Shirasawa Masayuki, Masuda Ken, Matsumoto Yuji, Shinno Yuki, Yagishita Shigehiro, Okuma Yusuke, Goto Yasushi, Horinouchi Hidehito, Yamamoto Noboru, Motoi Noriko, Yatabe Yasushi, Ohe Yuichi |
| Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical lung cancer 2021 Mar . Kao Chester, Powers Eric, Wu Yuan, Datto Michael B, Green Michelle F, Strickler John H, Ready Neal E, Zhang Tian, Clarke Jeffrey |
| Effect of prior therapy on tumor mutational burden in NSCLC. Translational lung cancer research 2021 4 10 (3): 1231-1238. Jonna Sushma, Vanderwalde Ari, Nieva Jorge, Poorman Kelsey Anne, Saul Michelle, von Buttlar Xinyu, Hu John Y, Liu Stephen |
| SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Apr . Alessi Joao V, Ricciuti Biagio, Spurr Liam F, Gupta Hersh, Li Yvonne Y, Glass Carolyn, Nishino Mizuki, Cherniack Andrew D, Lindsay James, Sharma Bijaya, Felt Kristen D, Rodig Scott J, Cheng Michael L, Sholl Lynette M, Awad Mark |
| Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Translational lung cancer research 2021 3 10 (2): 826-838. Fung Andrea S, Karimi Maryam, Michiels Stefan, Seymour Lesley, Brambilla Elisabeth, Le-Chevalier Thierry, Soria Jean-Charles, Kratzke Robert, Graziano Stephen L, Devarakonda Siddhartha, Govindan Ramaswamy, Tsao Ming-Sound, Shepherd Frances |
| Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. Translational lung cancer research 2020 Dec 9 (6): 2367-2379. Xu Yanjun, Li Hui, Huang Zhiyu, Chen Kaiyan, Yu Xiaoqing, Sheng Jiamin, Zhang Han-Han, Fan Y |
| New methodology of TMB assessment from tissue and liquid biopsy in NSCLC. PloS one 2022 9 17 (9): e0275121. K?ížová ?udmila, Šafa?íková Markéta, Kalousová Marta, Pfeiferová Lucie, Kub?na Aleš Antonín, Vo?ka Michal, Ulrych Jan, Franková V?ra, Petruželka Luboš, Zima Tomáš, Feltl Dav |
| Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 2022 Sep . Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J |
| Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. Journal for immunotherapy of cancer 2022 2 10 (1): . Zheng Mi |
| Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. Therapeutic advances in medical oncology 2022 12 14 17588359221141761. Lee Jii Bum, Park Hyung Soon, Choi Su Jin, Heo Seong Gu, An Ho Jung, Kim Hye Ryun, Hong Min Hee, Lim Sun Min, Chang Kyle, Quinn Katie, Odegaard Justin, Shim Byoung Yong, Cho Byoung Ch |
| Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. Frontiers in oncology 2022 11 12 972972. Sun Daqiang, Xu Meilin, Pan Chaohu, Tang Hongzhen, Wang Peng, Wu Dongfang, Luo Hait |
| Genomic landscape of lung cancer in the young. Frontiers in oncology 2022 12 910117. Ruiz Rossana, Galvez-Nino Marco, Roque Katia, Montes Jaime, Nuñez Maria, Raez Luis, Sánchez-Gambetta Sergio, Jaúregui Sandra, Viale Sandra, Smith Edward S, Pinto Joseph A, Mas Lu |
| Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. Cancers 2022 May 14 (10): . Ulivi Paola, Urbini Milena, Petracci Elisabetta, Canale Matteo, Dubini Alessandra, Bartolini Daniela, Calistri Daniele, Cravero Paola, Fonzi Eugenio, Martinelli Giovanni, Priano Ilaria, Andrikou Kalliopi, Bronte Giuseppe, Crinò Lucio, Delmonte Ange |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
| Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications. Lung cancer (Amsterdam, Netherlands) 2023 8 184 107317. Huriye Seker-Cin, Timothy Kwang Yong Tay, Daniel Kazdal, Klaus Kluck, Markus Ball, Olaf Neumann, Hauke Winter, Felix Herth, Claus-Peter Heußel, Rajkumar Savai, Peter Schirmacher, Michael Thomas, Jan Budczies, Michael Allgäuer, Petros Christopoulos, Albrecht Stenzinger, Anna-Lena Volckm |
| Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung cancer (Amsterdam, Netherlands) 2023 1 176 103-111. Tamiya Yutaro, Matsumoto Shingo, Zenke Yoshitaka, Yoh Kiyotaka, Ikeda Takaya, Shibata Yuji, Kato Terufumi, Nishino Kazumi, Nakamura Atsushi, Furuya Naoki, Miyamoto Shingo, Kuyama Shoichi, Nomura Shogo, Ikeno Takashi, Udagawa Hibiki, Sugiyama Eri, Nosaki Kaname, Izumi Hiroki, Sakai Tetsuya, Hashimoto Naozumi, Goto Koic |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 01, 2023
- Content source: